Profil:
Synektik SASynektik medical expects revenue growth in 2024/25
Listed radiopharmaceuticals and medical solutions company Synektik assesses the market outlook positively and expects revenue growth from the perspective of the entire 2024/25 financial year, deputy CEO Dariusz Korecki told a videoconference. He currently estimates the market potential in the Baltics at a dozen da Vinci devices.
"With a successful quarter behind us, the outlook in the market is unchanged positive, even despite some turbulence not directly related to our business," Korecki said.
Normalised EBITDA in the first quarter of 2024/25 was PLN 51 million (EUR 12.2 mln) against PLN 53.1 million (EUR 12.7 mln) in the prior year period.
"We assume a positive change [in normalised EBITDA - PAP ed.] in the following quarters. This will be influenced by the sales structure - there are more devices in our portfolio used for therapy, rather than diagnostics, which gives us the opportunity to achieve a higher margin on a project, which then gives recurring revenues," Synektik's deputy CEO assessed.
Synektik said in a presentation that the backlog at the end of December 2024 in the medical equipment and IT solutions sales segment was PLN 4.3 million (EUR 1.03 mln) versus PLN 28.3 million (EUR 6.77 mln) a year earlier.
The value of active offers at the end of December 2024 was PLN 123.4 million (EUR 29.53 mln), up from PLN 99.5 million (EUR 23.81 mln) in the prior year period.
As reported, nine da Vinci systems were sold and installed in the first quarter of 2024/25 (eight in Poland and one in Slovakia). Eight systems were made available to tenants in Poland.
doa/ ao/
